Galectin Therapeutics, Inc. (GALT) Stock: Here’s Why It’s Gaining


Galectin Therapeutics, Inc. (GALT) is working its way for to the top in the market today. The stock, focused in the biotechnology sector, is currently trading at $4.15 after a move up of 7.79% so far today. As it relates to biotech stocks, there are quite a few factors that have the potential to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines centered around GALT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-17-19 08:00AM Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Sep-11-19 10:13AM Small Drug Stock Outlook: Innovation Holds the Key to Growth
Aug-27-19 03:21PM Need To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying Shares
10:21AM New Strong Buy Stocks for August 27th
09:00AM FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%

However, any time investors are making a decision with regard to investing, prospective investors should look into far more than news, especially in the highly speculative biotechnology space. Here’s what’s happening in regard to Galectin Therapeutics, Inc..

The Performance That GALT Investors Have Experienced

While a gain in a single session, like the move that we’re seeing from Galectin Therapeutics, Inc. may cause excitement in some investors, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always a good idea to look at trends just a single trading session. As it relates to GALT, below are the movements that investors have seen:

  • Past 5 Trading Sessions – Over the past 5 trading sessions, GALT has generated a price change amounting to 13.08%.
  • Monthly – The ROI from Galectin Therapeutics, Inc. in the last 30 days works out to 10.08%.
  • Past 3 Months – Throughout the last quarter, the stock has produced a ROI of 4.01%
  • Past 6 Months – Over the past 6 months, we have seen a performance that amounts to -11.51% from the stock.
  • YTD – Since the the last trading session of last year GALT has produced a return on investment of 20.99%.
  • Full Year – Finally, throughout the past full year, we have seen movement amounting to -22.72% from GALT. In this period, the stock has sold at a high of -32.61% and a low of 41.16%.

Rations That Traders Should Look Into

Digging into a few ratios having to do with a stock can give investors a look of just how dangerous and/or potentially profitable a pick might be. Here are some of the key ratios to consider when digging into GALT.

Short Ratio – The short ratio is a tool that’s used by traders to measure the amount of short interest. As the ratio heads up, it means that more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, in regard to Galectin Therapeutics, Inc., the stock’s short ratio clocks in at 14.87.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure whether or not a company can cover its debts when they come due with only current assets or quick assets. In the biotechnology space, companies are reliant on continued support from investors, these ratios can look damning. Nonetheless, several gems in the biotechnology industry come with great current and quick ratios. As it relates to GALT, the quick and current ratios work out to 40.00 and 40.00 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. In the case of Galectin Therapeutics, Inc., that ratio works out to 0.98.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a biotech stock, this is a very important ratio to look into. In the case of GALT, the cash to share value ratio works out to 0.93.

Analyst Opinions With Regard To Galectin Therapeutics, Inc.

Although it’s never a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their thoughts when validating your own before making an investment decision in the biotechnology industry. Here are the most recent moves that we have seen from analysts as it relates to GALT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-13-19 Initiated B. Riley FBR Buy $11
Dec-07-17 Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17 Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17 Initiated ROTH Capital Buy
Mar-30-17 Upgrade H.C. Wainwright Neutral → Buy $3.50

What Are Big Money Players Doing With Galectin Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in GALT, here’s what we’re seeing:

Institutions own 15.10% of the company. Institutional interest has moved by 0.22% over the past three months. When it comes to insiders, those who are close to the company currently own 14.40% percent of GALT shares. Institutions have seen ownership changes of an accumulative 144.55% over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 56.05M shares of Galectin Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, GALT has a float of 40.58M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to GALT, the short percent of the float is 9.78%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.46. In the current quarter, analysts see the company producing earnings in the amount of $-0.09. Over the last 5 years, GALT has generated revenue in the amount of $0 with earnings coming in at 21.70%. On a quarter over quarter basis, earnings have seen movement of 43.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here